Certara, Inc.
$10.55-$0.13 (-1.2%)
Last close · Data as of Nov 20, 2026
- Market cap
- $872.7M
- P/E
- -547.2x
- EV / EBITDA
- 9.7x
- Revenue
- $418.8M
- Net margin
- -0.4%
- ROCE
- 1.5%
Price chart
Technical chartScreen technicals →+31.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +7.8%
- 3M
- +20.8%
- 6M
- +125.9%
- 1Y
- +31.4%
- 5Y
- -65.4%
52-week range
Day change -$0.13 (-1.2%) from $10.68 to $10.55 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in CERT, bought on each weekday since 2021.
News & filings
What Certara filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 1.6 million US dollars in fiscal 2025.
Strengths (1)
- EBITDA grew 41.7% in fiscal 2025, 32.9 points more than revenue.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Read moreShow less
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
- Sector
- Healthcare
- Shares outstanding
- 159.1M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $872.7M
- P/E
- -547.2x
- P/B
- 0.8x
- EV / EBITDA
- 9.7x
- EV / Sales
- 2.4x
- P/S
- 2.1x
- 52-week high
- $12.22
- 52-week low
- $4.48
Profitability
- Operating margin
- 5.0%
- Net margin
- -0.4%
- EBITDA margin
- 24.5%
- ROE
- -0.2%
- ROCE
- 1.5%
- ROA
- -0.1%
- Asset turnover
- 0.27
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $418.8M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 8.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 7.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -86.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $69.8M
Solvency
- Current ratio
- 2.05
- Debt / Equity
- 0.29
- Debt / Assets
- 0.20
- CFO / Net profit
- -60.39
- Cash / Market cap
- 21.7%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $418.8M |
| Cost of revenue | $161.1M |
| Gross profit | $257.7M |
| Operating expenses | $236.7M |
| Research and development | $41.0M |
| Selling, general and administrative | $139.1M |
| Operating income | $21.0M |
| Interest and other | -$13.4M |
| Pretax income | $7.6M |
| Tax and other | $9.2M |
| Net income | -$1.6M |
Revenue and net profit
Revenue grew 8.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $335.6M | $14.7M |
| FY2023 | $354.3M | -$55.4M |
| FY2024 | $385.1M | -$12.1M |
| FY2025 | $418.8M | -$1.6M |
Cash flows
FY2025: $96.3M from operations, $69.8M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $92.5M | $80.0M |
| FY2023 | $82.8M | $67.4M |
| FY2024 | $80.5M | $59.4M |
| FY2025 | $96.3M | $69.8M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $418.8M+8.7%1Y
- EBITDA
- $102.5M+41.7%1Y
- Net profit
- -$1.6M
- Cash from operations
- $96.3M+19.7%1Y
- Free cash flow
- $69.8M+17.4%1Y
- Revenue CAGR, 3Y
- 7.7%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $418.8M | $102.5M | -$1.6M | $69.8M | -0.2% | +8.7% | -86.8% |
Monthly returns
Month-by-month returns of CERT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.6B |
| Current assets | $315.1M |
| Non-current assets | $1.2B |
| Liabilities | $493.8M |
| Current liabilities | $153.4M |
| Non-current liabilities | $340.4M |
| Equity | $1.1B |
| Paid-in capital | $1.3B |
| Retained earnings | -$129.9M |
| Treasury stock | $66.7M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CERT highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Annexon, Inc., Cullinan Therapeutics, Inc., Jade Biosciences, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Certara, Inc.CERTthis company | $872.7M | -547.2x | 0.8x | -0.2% | 9.7x |
| Annexon, Inc.ANNX | $892.9M | -4.3x | 4.2x | -97.7% | -3.5x |
| Pacira BioSciences, Inc.PCRX | $892.0M | 126.9x | 1.3x | 1.0% | 8.7x |
| Xencor, Inc.XNCR | $890.4M | — | 1.4x | -14.5% | — |
| Cullinan Therapeutics, Inc.CGEM | $886.8M | -4.0x | 2.2x | -53.8% | -3.3x |
| MeiraGTx Holdings plcMGTX | $886.3M | -7.8x | -153.0x | 1971.4% | -10.2x |
| Jade Biosciences, Inc.JBIO | $875.6M | — | -18.7x | -38.3% | — |
| Talkspace, Inc.TALK | $871.1M | 111.8x | 7.4x | 6.7% | 129.1x |
| Arbutus Biopharma CorporationABUS | $859.3M | -25.6x | 11.2x | -43.7% | -25.5x |
| Peer median | — | -4.2x | 1.8x | -26.4% | -3.4x |
Year-to-date ROI
CERT since 1 January, against earlier years.
Historical volatility
CERT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 9.7% |
| FY2023 | 1.8% |
| FY2024 | -0.4% |
| FY2025 | 5.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $418.8M |
| Cost of revenueCost Of Revenue | $161.1M |
| Gross profitGross Profit | $257.7M |
| Operating expensesOperating Expense | $236.7M |
| Research and developmentResearch And Development | $41.0M |
| Selling, general and administrativeSelling General And Administration | $139.1M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $56.6M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $56.6M |
| Depreciation income statementDepreciation Income Statement | — |
| Amortization | — |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | — |
| Total expensesTotal Expenses | $397.8M |
| Operating incomeOperating Income | $21.0M |
| Interest and other | |
| Pretax incomePretax Income | $7.6M |
| TaxTax Provision | $9.2M |
| Net incomeNet Income | -$1.6M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.6B |
| Current assetsCurrent Assets | $315.1M |
| Non-current assetsTotal Non Current Assets | $1.2B |
| LiabilitiesTotal Liabilities Net Minority Interest | $493.8M |
| Current liabilitiesCurrent Liabilities | $153.4M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $340.4M |
| EquityTotal Equity Gross Minority Interest | $1.1B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $96.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $96.3M |
| Net income, continuing operationsNet Income From Continuing Operations | -$1.6M |
| Depreciation and amortisationDepreciation And Amortization | $75.2M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $75.2M |
| Depreciation | — |
| Amortization cash flowAmortization Cash Flow | — |
| Amortization of intangiblesAmortization Of Intangibles | — |
| Stock-based compensationStock Based Compensation | $33.1M |
| Deferred taxDeferred Tax | -$8.3M |
| Deferred income taxDeferred Income Tax | -$8.3M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Asset impairmentAsset Impairment Charge | $0.00 |
| Provision and write off of assetsProvisionand Write Offof Assets | $1.1M |
| Change in working capitalChange In Working Capital | $910.0k |
| Other non-cash itemsOther Non Cash Items | -$4.1M |
| Investing cash flowInvesting Cash Flow | -$26.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$26.6M |
| Capital expenditureCapital Expenditure | -$26.6M |
| Capital expenditure (reported)Capital Expenditure Reported | -$26.6M |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | $0.00 |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | $0.00 |
| Financing cash flowFinancing Cash Flow | -$64.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$64.0M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$3.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$3.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$3.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$3.0M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | -$42.6M |
| Common stock repurchasedCommon Stock Payments | -$42.6M |
| Share buybacksRepurchase Of Capital Stock | -$42.6M |
| Other financing chargesNet Other Financing Charges | -$18.4M |
| Change in cashChanges In Cash | $5.8M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 443.0% |
| Cash at the start of the yearBeginning Cash Position | $179.2M |
| Cash at the end of the yearEnd Cash Position | $189.4M |
| Free cash flowFree Cash Flow | $69.8M |
| Supplemental |
Learn while you research
Academy chapters picked for Certara, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read